Public Production of Medicines and HIV/AIDS Activists: New Actors in the Generic Drug Regulatory Process

  • Elize Massard da FonsecaEmail author
Part of the SpringerBriefs in Political Science book series (BRIEFSPOLITICAL, volume 26)


This chapter turns now to assess the stakeholders that question the current architecture of the pharmaceutical regulation in Brazil. There is an increasing apprehension among AIDS activists about the stringency of Brazil’s regulation for generic medicines, citing that these rules might limit competition and undermine access to medicines. Similarly, public pharmaceutical factories have voiced their struggle to adapt to this norm for different reasons and questioned the necessity of such strict regulation. The first section analyses the effects of generic drug regulation on the public production of medicines. This also serves as background information to the following section that assesses AIDS activists’ preferences and demands.


Human Immunodeficiency Virus Intellectual Property Generic Drug Immune Deficiency Syndrome Public Producer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Center for Public Administration and Government Studies, São Paulo Business SchoolGetulio Vargas FoundationSão PauloBrazil

Personalised recommendations